NCT07653100 RSVpreF Respiratory Syncytial Virus Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07653100 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 4 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why NCT07653100 is a hot trial to watch
Respiratory Syncytial Virus Infections is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07653100 is notable because it evaluates RSVpreF in a Phase 3 design sponsored by Pfizer Inc.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07653100 |
| Official title | A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF |
| Phase / status | Phase 3 / Recruiting |
| Intervention | RSVpreF |
| Sponsor | Pfizer Inc. |
| Geography | India |
| Enrollment | [object Object] |
| Primary endpoint | Proportion of participants reporting local reactions within 7 days following investigational product administration |
| Endpoint time frame | Within 7 days |
| Primary completion / readout proxy | [object Object] |
Protocol design and endpoint interpretation
The purpose of this phase 3 multicenter, double-blinded, placebo-controlled study in India is to learn about the safety and immunogenicity of RSVpreF in adults.
Allocation is Randomized, masking is Double, and the intervention model is Parallel Assignment. Planned enrollment of [object Object] participants across India shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Proportion of participants reporting local reactions within 7 days following investigational product administration (Within 7 days) — Describe local reactions following investigational product administration
- Percentage of participants reporting systemic events within 7 days following investigational product administration (Within 7 days) — Describe systemic events following investigational product administration
- Percentage of participants reporting adverse events (AEs) through 1 month following investigational product administration (1 month after vaccination) — Describe AEs occurring through 1 month following administration of investigational product
- Percentage of participants reporting serious adverse events (SAEs) throughout the study (3 months after vaccination) — Describe SAEs through 3 months following administration of investigational product
Readout outlook and evidence gap
The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: RSVpreF is indexed as No normalized modality returned, with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status No normalized global status returned.
Company & Deal Intelligence MCP profile: Pfizer Inc. is resolved to a normalized organization record in United States. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
NCT07653100 provides a focused lens on Respiratory Syncytial Virus Infections development. Its value will be determined by whether RSVpreF can convert the current Phase 3 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
